Skip to main content
SpringerLink
Log in

Economic Burden of Haematological Adverse Effects in Cancer Patients

A Systematic Review

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: Patients receiving cancer treatments commonly experience haematological adverse effects (AEs) related to chemotherapy or molecularly targeted therapies, which may be associated with high healthcare costs. The objective of this review was to summarise the published literature on the economic burden of neutropenia, thrombocytopenia and anaemia as AEs of cancer treatment.

Methods: A systematic search of the medical literature published between 1990 and 2006 was conducted using PubMed/MEDLINE, EMBASE, BIOSIS, related article links and supplemental searches. References selected for inclusion were prospective or retrospective studies specifically designed to examine the burden of illness, direct medical costs, indirect costs and/or cost drivers associated with neutropenia, thrombocytopenia and anaemia in adult cancer patients. All costs are reported as originally published and adjusted to 2006 US dollars.

Results: In the US, the cost of neutropenia ranged from $US1893 (2006 value $US2632) per outpatient episode to $US38 583 ($US49 917) per febrile neutropenia hospitalisation. For countries outside the US, the cost of neutropenia appeared to be lower. The cost of thrombocytopenia ranged from $US1035 ($US1395) to $US5328 ($US7635) per cycle or episode in the US. Costs attributable to anaemia ranged from $US18 418 ($US22 775) to $US69 478 ($US93 454) per year in the US. The costs of AEs for patients with haematological malignancies appeared to be up to 2–3 times higher than those for patients with solid tumours. Economic studies of the cost of haematological AEs specific to new molecularly targeted treatments for haematological malignancy have not been published.

Conclusions: Chemotherapy-related haematological AEs result in a substantial economic burden on patients, payers, caregivers and society in general. Because of their burden, the frequency and severity of these toxicities should be one of the key factors in the selection of optimal treatments for patients with cancer, especially those with haematological malignancies. Future research is needed to assess the economic burden of AEs associated with new molecularly targeted treatments for haematological malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Fig. 2
Fig. 3
Table IX
Fig. 4

Similar content being viewed by others

References

  1. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005 May 1; 103(9): 1916–24

    Article  PubMed  Google Scholar 

  2. Cosier LE, Calhoun EA, Agboola O, et al. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004; 24(4): 488–94

    Article  Google Scholar 

  3. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005 September 8; 353(10): 988–98

    Article  PubMed  CAS  Google Scholar 

  4. Donohue R. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncol Nurs Forum 2006 March; 33(2): 347–52

    Article  PubMed  Google Scholar 

  5. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002 Dec 15; 20(24): 4636–42

    Article  PubMed  Google Scholar 

  6. Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997 June 19; 336(25): 1776–80

    Article  PubMed  CAS  Google Scholar 

  7. Cantor SB, Elting LS, Hudson Jr DV, et al Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003 June 15; 97(12): 3099–106

    Article  PubMed  CAS  Google Scholar 

  8. Aledort LM, Mohandas K. Transfusion requirements in patients with malignancy. Semin Hematol 1996 January; 33(1 Suppl. 1): 6–9

    PubMed  CAS  Google Scholar 

  9. Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 2001 April; 84Suppl. 1: 31–7

    Article  PubMed  CAS  Google Scholar 

  10. Lyman GH, Berndt ER, Kailich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005 March; 8(2): 149–56

    Article  PubMed  Google Scholar 

  11. Hassett MJ, O’Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006 August 16; 98(16): 1108–17

    Article  PubMed  Google Scholar 

  12. Bristol Myers Squibb Co. Dasatinib (SPRYCEL) product information. Princeton (NJ)/ Bristol Myers Squibb Co 2006

  13. Cosier LE, Sivasubramaniam V, Agboola O, et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005 January; 8(1): 47–52

    Article  Google Scholar 

  14. Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001; 6(5): 441–5

    Article  PubMed  CAS  Google Scholar 

  15. Chrischilles EA, Klepser DG, Brooks JM, et al. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin’s lymphoma cases during first-course chemotherapy. Pharmacotherapy 2005 May; 25(5): 668–75

    Article  PubMed  Google Scholar 

  16. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006 May 15; 106(10): 2258–66

    Article  PubMed  Google Scholar 

  17. Cantor SB, Rubenstein EB, Elting LS, et al. Economic evaluation of management strategies for low risk febrile neutropenic cancer patients [abstract no. 1498]. Proc Am Soc Clin Oncol 1997

  18. Del Prete SA, Ryan SP, Jacobson JS, et al. Safety and costs of treating neutropenic fever in an outpatient setting. Conn Med 1999 December; 63(12): 713–7

    PubMed  Google Scholar 

  19. Gandhi SK, Arguelles L, Boyer JG. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy 2001 June; 21(6): 684–90

    Article  PubMed  CAS  Google Scholar 

  20. Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998 Nov; 34(12): 1857–64

    Article  PubMed  CAS  Google Scholar 

  21. Glaspy JA, Bleecker G, Crawford J, et al. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 1993; 29ASuppl. 7: S23–30

    Article  PubMed  Google Scholar 

  22. Glaspy JA, Bleecker GC, Crawford J, et al. Decreased costs in cancer chemotherapy patients using recombinant granulocyte colony stimulating factor. Clin Res 1991; 39(1): 7A

    Google Scholar 

  23. Minisini A, Spazzapan S, Crivellari D, et al. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Crit Rev Oncol Hematol 2005 Feb; 53(2): 125–31

    Article  PubMed  CAS  Google Scholar 

  24. Annemans L, Giaccone G, Vergnenegre A. The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis. Anticancer Drugs 1999 Jul; 10(6): 605–15

    Article  PubMed  CAS  Google Scholar 

  25. Herold M, Hieke K. Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine. Eur J Health Econ 2002; 3(3): 166–72

    Article  PubMed  CAS  Google Scholar 

  26. Dranitsaris G, Tran TM. Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 1995; 31A(13-14): 2174–80

    Article  PubMed  CAS  Google Scholar 

  27. Dranitsaris G, Tran TM, McGeer A, et al. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 1995; 7(1): 49–62

    Article  PubMed  CAS  Google Scholar 

  28. Korpela J, Salminen E. Neutropenic infections add significant costs to palliative chemotherapy in breast cancer. Anticancer Res 2002; 22(2B): 1337–40

    PubMed  Google Scholar 

  29. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93(1): 31–8

    Article  PubMed  CAS  Google Scholar 

  30. Mayordomo JI, Rivera F, az-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87(11): 803–8

    Article  PubMed  CAS  Google Scholar 

  31. Montera MC, Valdivia ML, Carvajal E, et al. Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 1994 Aug 5; 16(4): 187–92

    Article  Google Scholar 

  32. Hackshaw A, Sweetenham J, Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin’s lymphoma? Br J Cancer 2004; 90(7): 1302–5

    Article  PubMed  CAS  Google Scholar 

  33. Leese B, Collin R, Clark DJ. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 1994; 6(3): 233–9

    Article  PubMed  CAS  Google Scholar 

  34. Leese B. The costs of treating febrile neutropenia in six U.K. Hospitals. Eur J Cancer 1993; 29ASuppl. 7: S15–8

    Article  PubMed  Google Scholar 

  35. Elting LS, Cantor SB. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Support Care Cancer 2002; 10(3): 189–96

    Article  PubMed  Google Scholar 

  36. Bennett CL, Stinson TJ, Laver JH, et al. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma 2000; 37(1-2): 65–70

    Article  PubMed  CAS  Google Scholar 

  37. Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003; 97(6): 1541–50

    Article  PubMed  Google Scholar 

  38. Malone D, Sullivan S, Black D, et al. The cost of treating chemotherapy-induced thrombocytopenia [abstract no. 887]. Proc Am Soc Clin Oncol 1995

  39. Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339(11): 746–54

    Article  PubMed  CAS  Google Scholar 

  40. Snider C, Erder H, LaBrecque J, et al. What are the true costs of platelet transfusions? A prospective time motion study of resource utilization associated with platelet transfusions at UCLA Medical Center [abstract]. Blood 1996; 88: 333a

    Google Scholar 

  41. Balducci L, Benson K, Lyman GH, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. Transfusion 1993; 33(8): 665–70

    Article  PubMed  CAS  Google Scholar 

  42. Najib MM, Katz LM, Fastenau J, et al. Costs and epidemiology of myelosuppression in chemotherapy-treated metastatic breast cancer patients [abstract no. 2775]. Blood 2003 Nov 16; 102: 11

    Google Scholar 

  43. Berndt E, Crown W, Kallich J, et al. The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 2005; 23(2): 183–92

    Article  PubMed  Google Scholar 

  44. Nissenson AR, Wade S, Goodnough T, et al. Economic burden of anemia in an insured population. J Manag Care Pharm 2005; 11(7): 565–74

    PubMed  Google Scholar 

  45. Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health 2005; 8(6): 629–38

    Article  PubMed  Google Scholar 

  46. Lyman GH, Berndt E, Crown W, et al. Anemia is associated with high cost in newly diagnosed cancer patients [abstract]. Blood 2001 Nov 16; 98 (11 Part 2): 414b

    Article  Google Scholar 

  47. Cersosimo RJ, Jacobson DR. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia. Ann Pharmacother 2006; 40(1): 58–65

    PubMed  CAS  Google Scholar 

  48. Cremieux P, Greenberg P, Piech CT. Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anemia [abstract no. 2248]. Proc Am Soc Clin Oncol 2003

  49. Sheffield R, Sullivan SD, Saltiel E, et al. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 1997; 31(1): 15–22

    PubMed  CAS  Google Scholar 

  50. Cremieux PY, Finkelstein SN, Berndt ER, et al. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999; 16 (5 Pt 1): 459–72

    Article  PubMed  CAS  Google Scholar 

  51. Meadowcroft AM, Gilbert CJ, Maravich-May D, et al. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm 1998; 55(18): 1898–902

    PubMed  CAS  Google Scholar 

  52. Marchetti M, Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 2004; 22(16): 1029–45

    Article  PubMed  CAS  Google Scholar 

  53. Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health Syst Pharm 2005; 62(24): 2597–603

    Article  PubMed  Google Scholar 

  54. Cremieux PY, Barrett B, Anderson K, et al. Cost of outpatient blood transfusion in cancer patients. J Clin Oncol 2000; 18(14): 2755–61

    PubMed  CAS  Google Scholar 

  55. Cantor SB, Hudson Jr DV, Lichtiger B, et al. Costs of blood transfusion: a process-flow analysis. J Clin Oncol 1998; 16(7): 2364–70

    PubMed  CAS  Google Scholar 

  56. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995 May; 35(5): 427–30

    Article  PubMed  CAS  Google Scholar 

  57. Forbes JM, Anderson MD, Anderson GF, et al. Blood transfusion costs: a multicenter study. Transfusion 1991 May; 31(4): 318–23

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Material contained in this paper has been previously presented at the American Society of Hematology meeting (9–12 December 2006) in Orlando, FL, USA.

This review was supported by Novartis Pharmaceuticals Corporation. Dr Feng is an employee of Novartis Pharmaceuticals. The other authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Pharmerit North America LLC, 7272 Wisconsin Avenue, Suite 300, Bethesda, Maryland, 20814, USA

    S. Y. Liou,  J. M. Stephens, K. T. Carpiuc & M. F. Botteman

  2. Johns Hopkins School of Public Health, Baltimore, Maryland, USA

    S. Y. Liou

  3. Novartis Pharmaceuticals, Florham Park, New Jersey, USA

    W. Feng

  4. University of Southern California, Los Angeles, California, USA

    J. W. Hay

Authors
  1. S. Y. Liou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. T. Carpiuc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. F. Botteman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. W. Hay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Stephens.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liou, S.Y., Stephens, J.M., Carpiuc, K.T. et al. Economic Burden of Haematological Adverse Effects in Cancer Patients. Clin. Drug Investig. 27, 381–396 (2007). https://doi.org/10.2165/00044011-200727060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200727060-00002

Keywords

Search

Navigation